These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 17177114)

  • 1. Influence of realistic inspiratory flow profiles on fine particle fractions of dry powder aerosol formulations.
    Martin GP; Marriott C; Zeng XM
    Pharm Res; 2007 Feb; 24(2):361-9. PubMed ID: 17177114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
    Marriott C; MacRitchie HB; Zeng XM; Martin GP
    Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between inertial impaction and laser diffraction sizing data for aerosolized carrier-based dry powder formulations.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Pharm Res; 2006 Sep; 23(9):2200-9. PubMed ID: 16900411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of a carrier-free dry powder aerosol formulation using inertial impaction and laser diffraction.
    Martin GP; MacRitchie HB; Marriott C; Zeng XM
    Pharm Res; 2006 Sep; 23(9):2210-9. PubMed ID: 16900410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 1. Albuterol sulfate and disodium cromoglycate.
    Xu Z; Mansour HM; Mulder T; McLean R; Langridge J; Hickey AJ
    J Pharm Sci; 2010 Aug; 99(8):3398-414. PubMed ID: 20198688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro.
    Srichana T; Martin GP; Marriott C
    Eur J Pharm Sci; 1998 Dec; 7(1):73-80. PubMed ID: 9845780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of different grades of lactose as a carrier for aerosolised salbutamol sulphate.
    Larhrib H; Zeng XM; Martin GP; Marriott C; Pritchard J
    Int J Pharm; 1999 Nov; 191(1):1-14. PubMed ID: 10556735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of mixing of fine carrier particles on dry powder inhalation property of salbutamol sulfate (SS)].
    Iida K; Leuenberger H; Fueg LM; Müller-Walz R; Okamoto H; Danjo K
    Yakugaku Zasshi; 2000 Jan; 120(1):113-9. PubMed ID: 10655787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate.
    Tee SK; Marriott C; Zeng XM; Martin GP
    Int J Pharm; 2000 Nov; 208(1-2):111-23. PubMed ID: 11064216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of loaded carrier mass and formulation mass on aerosolization efficiency in dry powder inhaler devices.
    Ooi J; Gill C; Young PM; Traini D
    Curr Drug Deliv; 2015; 12(1):40-6. PubMed ID: 25146438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The contribution of different formulation components on the aerosol charge in carrier-based dry powder inhaler systems.
    Hoe S; Traini D; Chan HK; Young PM
    Pharm Res; 2010 Jul; 27(7):1325-36. PubMed ID: 20354768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Granulated Lactose as a Carrier for Dry Powder Inhaler Formulations 2: Effect of Drugs and Drug Loading.
    Du P; Du J; Smyth HDC
    J Pharm Sci; 2017 Jan; 106(1):366-376. PubMed ID: 27939234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dry powder formulations for inhalation of fluticasone propionate and salmeterol xinafoate microcrystals.
    Murnane D; Martin GP; Marriott C
    J Pharm Sci; 2009 Feb; 98(2):503-15. PubMed ID: 18506819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
    Le VN; Bierend H; Robins E; Steckel H; Flament MP
    Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of carrier morphology on drug delivery by dry powder inhalers.
    Zeng XM; Martin GP; Marriott C; Pritchard J
    Int J Pharm; 2000 Apr; 200(1):93-106. PubMed ID: 10845690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 2. Ipratropium bromide monohydrate and fluticasone propionate.
    Xu Z; Mansour HM; Mulder T; McLean R; Langridge J; Hickey AJ
    J Pharm Sci; 2010 Aug; 99(8):3415-29. PubMed ID: 20222025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery.
    Zeng XM; Martin GP; Marriott C; Pritchard J
    J Pharm Sci; 2001 Sep; 90(9):1424-34. PubMed ID: 11745794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation.
    Zeng XM; Martin GP; Tee SK; Ghoush AA; Marriott C
    Int J Pharm; 1999 May; 182(2):133-44. PubMed ID: 10341303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.